Last reviewed · How we verify

Nifedipine and Labetalol

The Cleveland Clinic · Phase 1 active Small molecule Quality 3/100

Nifedipine and Labetalol is a Small molecule drug developed by The Cleveland Clinic. It is currently in Phase 1 development. Also known as: Procardia and Trandete.

At a glance

Generic nameNifedipine and Labetalol
Also known asProcardia and Trandete
SponsorThe Cleveland Clinic
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Nifedipine and Labetalol

What is Nifedipine and Labetalol?

Nifedipine and Labetalol is a Small molecule drug developed by The Cleveland Clinic.

Who makes Nifedipine and Labetalol?

Nifedipine and Labetalol is developed by The Cleveland Clinic (see full The Cleveland Clinic pipeline at /company/the-cleveland-clinic).

Is Nifedipine and Labetalol also known as anything else?

Nifedipine and Labetalol is also known as Procardia and Trandete.

What development phase is Nifedipine and Labetalol in?

Nifedipine and Labetalol is in Phase 1.

What are the side effects of Nifedipine and Labetalol?

Common side effects of Nifedipine and Labetalol include symptomatic hypotenstion.

Related